Gait Changes Following Botulinum Toxin A Treatment in Stroke

REFERENCES

• Knutsson E, Richards C. Different types of disturbed motor control in gait of hemiparetic patients. Brain. 1979;102:405–430.
   PubMed Web of Science ®Google Scholar
• Olney Si, Richards C. Hemiparetic gait following stroke. Part I: characteristics. Gait Posture. 1996;4:136–148.
   Google Scholar
• Katz R, Rymer WZ. Spastic hypertonia: mechanisms and measurement. Arch Phys Med Rehabil.1989;70:144–155.
   PubMed Web of Science ®Google Scholar
• Rydahl Si, Brouwer BJ. Ankle stiffness and tissue compliance in stroke survivors: a validation of myotonometer measurements. Arch Phys Med Rehabi/.2004;85:1631–1637.
   PubMed Web of Science ®Google Scholar
• Sinkjaer T, Magnussen I. Passive, intrinsic, and reflex-mediated stiffness in the ankle extensors of hemiparetic patients. Brain. 1994;117:355–363.
   PubMed Web of Science ®Google Scholar
• O'Dwyer Ni, Ada L. Reflex hyperexcitability and muscle contracture in relation to spastic hypertonia. Curr Opin Neurol. 1996;9:451–455.
   PubMed Web of Science ®Google Scholar
• Lamontagne A, Malouin F, Richards CL. Locomotor-specific measure of spasticity of plantarflexor muscles after stroke. Arch Phys Med Rehabil.2001;82:1696–1704.
   PubMed Web of Science ®Google Scholar
• Lamontagne A, Malouin F, Richards CL, Dumas F. Mechanisms of disturbed motor control in ankle weakness during gait after stroke. Gait Posture. 2002;15:244–255.
   PubMed Web of Science ®Google Scholar
• Hesse S, Lucke D, Malezic M, Bertelt C, Friedrich H, Gregoric M, Mauritz KH. Botulinum toxin treatment for lower limb extensor spasticity in chronic hemiparetic patients. J Neurol Neurosurg Psychiatry. 1994;57:1321–1324.
   PubMed Web of Science ®Google Scholar
• Winter DA. The Biomechanics and Motor Control of Human Gait: Normal, Elderly and Pathological. Waterloo, Canada: University of Waterloo Press; 1991.
   Google Scholar
• Olney Si, Griffin MP, McBride I. Work and power in gait of stroke patients. Arch Phys Med Rehabil. 1991;72:309–314.
   PubMed Web of Science ®Google Scholar
• Blasi J, Chapman ER, Link E, et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature. 1993;365:160–163.
   PubMed Web of Science ®Google Scholar
• Burgen ASV, Dickens F, Zatman LJ. The action of botulinum toxin on the neuromuscular junction. I Physiol. 1949;109:10–24.
   PubMed Web of Science ®Google Scholar
• Gundersen CB. The effects of botulinum toxin on the synthesis, storage and release of acetylcholine. Prog Neurobiol. 1980;14:99–119.
   PubMed Web of Science ®Google Scholar
• Esquenazi A. Improvements in healthcare and cost benefits associated with botulinum toxin treatment of spasticity and muscle overactivity. Eur I Neurol. 2006;13:27–34.
   PubMed Web of Science ®Google Scholar
• Naumann M, Albanese A, Heinen F, Molenaers G, Relja M. Safety and efficacy of botulinum toxin type A following long term use. Fur I Neurol. 2006;14:35–40.
   Google Scholar
• Burbaud P, Wiart L, Dubos JL, et al. A randomized, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. I Neurol Neurosurg Psychiatry. 1996;61:265–269.
   PubMed Web of Science ®Google Scholar
• Reiter F, Danni M, Lagalla G, Ceravolo G, Provincialli L. Low-dose botulinum toxin with ankle taping for the treatment of spastic equinovarus foot after stroke. Arch Phys Med Rehabil.1998;79:535.
   Google Scholar
• Rousseaux M, Compere S, Launay MJ, Kozlowski O. Variability and predictability of functional efficacy of botulinum toxin injection in leg spastic muscles. J Neurol Sci. 2005;232:51–57.
   PubMed Web of Science ®Google Scholar
• Pierson SH, Katz DI, Tarsy D. Botulinum toxin A in the treatment of spasticity: functional implications and patient selection. Arch Phys Med Rehabil. 1996;77:717–721.
   PubMed Web of Science ®Google Scholar
• Bayram S, Sivrioglu K, Karli N, Ozcan O. Low dose botulinum toxin with short term electrical stimulation in poststroke spastic drop foot: a preliminary study. Am I Phys Med Rehabil. 2006;1:75–81.
   Web of Science ®Google Scholar
• Pittock SJ, Moore AP, Hardiman O, et al. A double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke. Cerebrovasc Dis. 2003;15: 289–300.
   PubMed Web of Science ®Google Scholar
• Parvataneni K, Olney SJ, Brouwer B. Changes in muscle group work associated with changes in gait speed of persons with stroke. Clin Biomech. 2007;22:813–820.
   PubMed Web of Science ®Google Scholar
• Mackey AH, Walt SE, Lobb G, Stott NS. Intraobserver reliability of the modified Tardieu scale in the upper limb of children with hemiplegia. Dev Med Child Neurol. 2004;46:267–272.
   PubMed Web of Science ®Google Scholar
• Robinson W, Smith R, Aung O, Ada L. No difference between wearing a night splint and standing on a tilt table in preventing ankle contracture early after stroke: a randomised trial. Aust I Physiother. 2008;54:33–38.
   PubMed Web of Science ®Google Scholar
• Mayer NH, Simpson DM. Dosing, administration, and a treatment algorithm for use of botulinum toxin A for adult-onset muscle overactivity in patients with an upper motoneuron lesion. In: Mayer NH, Simpson DM, eds. Spasticity: Etiology, Evaluation, Management and the Role of Botulinum Toxin. New York: We Move; 2002;154–165.
   Google Scholar
• Giladi N. The mechanism of action of Botulinum toxin type A in focal dystonia is most probably through its dual effect on efferent (motor) and afferent pathways at the injected site. I Neurol Sci. 1997;152:132–135.
   PubMed Web of Science ®Google Scholar
• Boyd RN, Pliatsios V, Starr R, Wolfe R, Graham HK. Biomechanical transformation of the gastroc-soleus muscle with botulinum toxin A in children with cerebral palsy. Dev Med Child Neurol. 2000;42:32–41.
   PubMed Web of Science ®Google Scholar
• Sutherland DH, Kaufman KR, Wyatt MP, Chambers HG, Mubarak SJ. Double-blind study of botulinum A toxin injections into the gastrocnemius muscle in patients with cerebral palsy. Gait Posture. 1999;10:1–9.
   PubMed Web of Science ®Google Scholar
• Zurcher AW, Molenaers G, Desloovere K, Fabry G. Kinematic and kinetic evaluation of the ankle after intramuscular injection of botulinum toxin A in children with cerebral palsy. Acta Orthopaedica Belgica. 2001;67:475–480
   PubMedGoogle Scholar
• Hesse S, Krajnik J, Luecke D, Jahnke MT, Gregoric M, Mauritz KH. Ankle muscle activity before and after botulinum toxin therapy for lower limb extensor spasticity in chronic hemiparetic patients. Stroke. 1996;27:455–460.
   PubMed Web of Science ®Google Scholar
• Mancini F, Sandrini G, Moglia A, Nappi G, Pacchetti C. A randomized, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (Botox) for the treatment of spastic foot. Neurol Sci. 2005;26:26–31.
   PubMed Web of Science ®Google Scholar
• Farina S, Migliorini C, Gandolfi M, et al. Combined effects of botulinum toxin and casting treatments on lower limb spasticity after stroke. Functional Neurol. 2008;23:87–91.
   PubMed Web of Science ®Google Scholar
• Johnson CA, Burridge JFI, Strike PW, Wood DE, Swain ID. The effect of the combined use of botulinum toxin type A and functional electrical stimulation in the treatment of spastic drop foot after stroke. Arch Phys Med Rehabil. 2004;85:902–909.
   PubMed Web of Science ®Google Scholar